Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation

Clinical Cancer Research

Volumn 16, Issue 17, 2010, Pages 4382-4391

  Redondo Muñoz, Javier ^a   Escobar Díaz, Elizabeth ^a   Del Cerro, Mercedes Hernández ^a   Pandiella, Atanasio ^c   Terol, María José ^d   García Marco, José A ^b   García Pardo, Angeles ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; API 2; ARSENIC TRIOXIDE; CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRICIRBINE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, CONFOCAL; MIDDLE AGED; OXIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 77956234118     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0072     Document Type: Article

References (41)

1. Rai KR. Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. Exp Hematol 2007;35:134-6.
2. Dighiero G, Hamblin TJ. Chronic lymphocytic leukemia. Lancet 2008; 371:1017-29.
3. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
4. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol 2009;6:405-18.
5. Bonati A, Rizzoli V, Lunghi P. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug. Curr Pharm Biotechnol 2006;7:397-405.
6. Efferth T, Li PCH, Badireenath Konkimalla VS, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007;13:353-61.
7. Dilda PJ, Hogg PJ. Arsenical-based drugs. Cancer Treat Rev 2007; 33:542-64.
8. Wang Z-Y, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008;111:2505-15.
9. Röllig C, Illmer T. The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma: a systematic review. Cancer Treat Rev 2009;35:425-30.
10. Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
11. Platanias LC. Biological responses to arsenic compounds. J Biol Chem 2009;284:18583-7.
12. Lunghi P, Costanzo A, Salvatore L, et al. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 2006;107:4549-53.
13. Tabellini G, Cappellini A, Tazzari PL, et al. Phosphoinositide 3-kinase/ Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005;202:623-34.
14. Ramos AM, Fernández C, Amrán D, Sancho P, de Blas E, Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005;105:4013-20.
15. Wen J, Cheng HY, Feng Y, et al. p38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 2008;140:169-80.
16. Davison K, Mann KK, Waxman S, Miller WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004;103:3496-502.
17. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci 2006;97:540-5.
18. Zhang W, Ohnishi K, Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia 1998;12:1383-91.
19. Bairey O, Vanichkin A, Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol 2010;32:e77-85, Epub ahead of print 2009 Feb 5.
20. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003;101: 4098-104.
21. Biswas S, Zhao X, Mone AP, et al. Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL in vitro. Leuk Res 2010;34:925-31.
22. Merkel O, Heyder C, Asslaber D, et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 2008;86: 541-52.
23. Barragán M, Campas C, Bellosillo B, Gil J. Protein kinases in the regulation of apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma 2003;44:1865-70.
24. Escobar-Díaz E, López-Martín EM, Hernández del Cerro M, et al. AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells. Interference with the Akt/NF-κB survival pathway. Leukemia 2005;19:572-9.
25. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Gene Dev 1999;13:2905-27.
26. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-12.
27. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol 2003;13:478-83.
28. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
29. Akgul C. Mcl-1 is a potencial therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009;66:1326-36.
30. Wetzler M, Brady MT, Tracy E, et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine phosphorylation. Clin Cancer Res 2006;12: 6817-25.
31. Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008;111:5152-62.
32. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-κB prevents apoptosis. Mol Cell Biol 2004;24: 1007-21.
33. Van Themsche C, Leblanc V, Parent S, Asselin E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content and compartmentalization. J Biol Chem 2009;284:20462-6.
34. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133:403-14.
35. Wang R, Li H, Guo G, et al. Augmentation by carnosic acid of apoptosis in human leukaemia cells induced by arsenic trioxide via upregulation of the tumour suppressor PTEN. J Int Med Res 2008;36:682-90.
36. Papa S, Bubici C, Zazzeroni F, et al. The NF-κB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 2006;13:712-29.
37. Wang Q, Zhou Y, Wang X, Chung DH, Evers BM. Regulation of PTEN expression in intestinal epithelial cells by c-Jun NH2-terminal kinase activation and nuclear factor-κB inhibition. Cancer Res 2007;67: 7773-81.
38. Vivanco I, Palaskas N, Tran C, et al. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007;11:555-69.
39. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008;27:6245-51.
40. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46: 219-34.
41. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.